Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.

Cancer research communications - 1 Feb 2026

Traichel Jasmin, Metzger Ariane, Walz Maria, Feuerstein Reinhild, Wohlfeil Nadine, Metzger Patrick, Marx Lisa, Asdih Célia, Lindenthal Agnes, Seger Alina, Schrimpf Jule, Nardella Luigi L, Kowar Silke, Frew Ian J, Halbach Sebastian, Kesselring Rebecca, Boerries Melanie, Griffin Ricarda, Brummer Tilman

Abstract excerpt

Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and...

Topics

Join the communities discussing this publication.

EGFR gene
Cell Line, Tumor
Colorectal Neoplasms
BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 41566838
DOI: 10.1158/2767-9764.CRC-25-0599
PMCID: PMC13037773

Genes

EGFR
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.PMID 41566838Read ↗

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancerSemantic proximity Read ↗

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.Semantic proximity Read ↗

Transcriptomic Analyses and Novel Organoid and Xenograft Modeling Reveals Potential Drug Sensitivities in a KRAS G12V-Mutant Colorectal Cancer Brain MetastasisSemantic proximity Read ↗

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.Semantic proximity Read ↗

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumorsSemantic proximity Read ↗

Modeling colorectal cancer: A bio‐resource of 50 patient‐derived organoid linesSemantic proximity Read ↗

Molecular and cellular phenotypic differences distinguish murine syngeneic models from human tumorsSemantic proximity Read ↗

A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis.Semantic proximity Read ↗

Heterogeneity, Inherent and Acquired Drug Resistance in Patient-Derived Organoids Models of Primary Liver CancerSemantic proximity Read ↗

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.Semantic proximity Read ↗

Challenges and Prospects of Patient-Derived Xenografts for Cancer ResearchSemantic proximity Read ↗

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.